Seondeuk Kim, Seon-Jae Ahn, Han Sang Lee, Woo-Jin Lee, Jangsup Moon, Jin Kyun Park, Kon Chu
{"title":"Direct brain involvement of Takayasu arteritis treated with rituximab and infliximab: a case report.","authors":"Seondeuk Kim, Seon-Jae Ahn, Han Sang Lee, Woo-Jin Lee, Jangsup Moon, Jin Kyun Park, Kon Chu","doi":"10.47936/encephalitis.2021.00108","DOIUrl":null,"url":null,"abstract":"<p><p>Takayasu arteritis (TAK) is a systemic vasculitis involving large arteries. Reports of direct central nervous system (CNS) involvement in TAK are extremely rare in the literature. In addition, treatment for direct involvement has not been reported. Herein, we describe a case of encephalitis in a TAK patient who presented with fever and headache at the first attack, then cognitive impairment at the second attack. The patient improved with rituximab and especially infliximab. These findings indicate the usefulness of rituximab and infliximab to treat the direct CNS manifestations in TAK.</p>","PeriodicalId":72904,"journal":{"name":"Encephalitis (Seoul, Korea)","volume":"2 1","pages":"9-13"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/61/aa/encephalitis-2021-00108.PMC10295906.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Encephalitis (Seoul, Korea)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47936/encephalitis.2021.00108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Takayasu arteritis (TAK) is a systemic vasculitis involving large arteries. Reports of direct central nervous system (CNS) involvement in TAK are extremely rare in the literature. In addition, treatment for direct involvement has not been reported. Herein, we describe a case of encephalitis in a TAK patient who presented with fever and headache at the first attack, then cognitive impairment at the second attack. The patient improved with rituximab and especially infliximab. These findings indicate the usefulness of rituximab and infliximab to treat the direct CNS manifestations in TAK.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
